MVM Life Science Partners said it plans to use the $233 million it raised for its 4th fund to invest in medical companies in the U.S. and Europe.
The Boston-and-London-based investment shop said the fund is its largest so far. MVM said it backs public and private companies at every stage of development, with investments of between $15 million and $30 million per company.
“We have had a very positive response from investors and we are delighted with the group of investors we have been able to attract,” founder & managing partner Dr. Stephen Reeders said in prepared remarks. “We believe the fund raising was helped by several factors including MVM’s compelling investment strategy, extensive track record, the strength of the team and our transatlantic presence with offices in London and Boston.”
MVM’s portfolio companies include AccuVein, Lombard Medical Technologies (NSDQ:EVAR), Cheetah Medical, Solx, and ZipLine Medical.